Indeed, os teopontin deep ly affec ts the proangiogenic potential of human monocytes. With regards to TNF, osteopontin enhances its expression in human mononuclear cells.In addition, the conditioned medium of recombinant osteopontintreated human monocy tes induces neovascu lar ization, while nosign if icantangiogenic Bimatoprost response was elicited by fresh medium added with the same dose of osteopontin.This report points to a role for mononuclear cell infilt ra te in med iating the ang iogen ic activity exerted invivo by osteopontin and underscores the relevance of proinflammatory cytokine, such as TNF, in this process.PROINFLAMMATORY AND ANTIANGIOGENIC CYTOKINES IL IL is a heterodimeric cytokine and is produced primarily by macrophages, monocytes and dendritic cells.Only IL p, consisting of a p and p chain, which are encoded by two separate genes, is biologically active. The biological activities of IL are mediated through high affinity receptors, where both ILR and ILR chains are required to generate a functional receptor.IL receptors are present primarily on natural killer and T cells and IL promotes IFN production and enhancement of cytolytic activity in T cells and NK cells. This is not unique to T helper lymphocytes, since macrophage TAM are a polarized M macrophage population.IL is a multifunctional cytokine and can cause tumour regression and reduce metastasis in animal models, due to the promotion of antitumour immunity and also to the significant inhibition of angiogenesis. IL is a strong antiangiogenic cytokine in vivo and such suppression is mediated through IFN. In fact, reports have shown that IL is not acting per se on EC but through IFN and that EC respond to IFN by induction of the chemokine IFN inducible protein, that is considered the ultimate mediator of the antiangiogenic activity of IL. There is in vitro evidence that IL inhibits VEGF produced by breast cancer cells and regulates stromal cell interactions, leading to dec reased matr ix me tallop ro te inase production. The same report shows that IL activates an antiangiogenic program in activated mouse spleen cells or human PBMC.Such effect does not require direct cellcell contact, yet result from continuous interaction between activated lymphoid cells and EC.By showing that in the presence of EC cells it is enhanced the inhibitory effects on MMP expression in activated PBMC, the authors confirm the angiostatic effects exerted by IL th rough thecross ta lk be tween inflamma to ry cellsand EC. Furthermore, the relevance of inflammatory cells present within the microenvironment of human lung tumours and their mobilization by local and sustained release of IL has been additionally pointed out by other recent reports where CD T cells kill tumours in situ by indirect effects of IFN. The efficacy of IL as anticancer as well as antivascular agent is still under intensive investigation.Novel data indicate that the therapeutic susceptibility of tumour vasculature to recombinant murine IL and, potentially, to other antivascular agents, is limited by its level of maturation. A developmental order, similar to that described during physiological neovascularization, is evident among vessels in growing tumours.This order markedly influenced tumour vessel response to antivascular therapy with recombinant IL, resulting in a reduced tumour vessel density, due to a decrease in angiogenic sprouts and induction of EC Carteolol hydrochloride apoptosis in pericytenegative vessels.